Compare Novo Nordisk A/S (NVO) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sea Limited — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while Sea Limited trades at $131.4 (market cap $80.55B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Sea Limited's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| NVO | SE | |
|---|---|---|
Market Cap | $207.85B | $80.55B |
Sector | Health | Media |
52-Week High | $63.98 | $196.50 |
52-Week Low | $35.29 | $78.16 |
Enterprise Value | $222.55B | $75.58B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SE stock trades at $129.71, up 12.99% on strong Q2 2026 results, with revenue of $7.8 billion (up 48% year-over-year) and net income of $458 million (up 11%). The technical picture is bullish with moving averages supporting the uptrend, though RSI levels indicate overbought conditions. Fundamentals show robust revenue growth and improving profitability, with net income margin reaching 6.36% in 2025. Analyst sentiment remains positive with a consensus buy rating and $128.33 price target.
The outlook for SE is favorable given accelerating growth across e-commerce, fintech, and gaming segments, but risks include margin pressure from increased investments and credit costs. The stock's high valuation multiples (P/E of 50.78) require sustained execution to justify further gains. Near-term resistance lies at $133, with support at $128.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
